Analysis for tumor recurrence.

Comparison of the SUH 2002–2011 and SUH 2002–2006 cohorts. Univariate recurrence-free survival analysis, including hazard ratio (HR) and 95% confidence interval (CI), for clinical and histopathological variables, and examined markers. (DOCX)</p

CK20, p53, andCD25 in representative urothelial bladder cancer tissue.

(A) Papillary urothelial carcinoma stained by Hematoxylin & Eosin (HE). (B) A consecutive section shows strong positivity for CK20 immunohistochemistry. (C) A p53 positive consecutive section, analyzed by the image analysis software, Visiopharm®. (D) Red indicates a positive nucleus, green indicates a nucleus with a staining intensity below the threshold value and blue indicates a negative nucleus. For illustration purposes, one hotspot of positive cells is identified and marked by a square. (E) A CD25 positive consecutive section, analyzed by the image analysis software, Visiopharm®. Red indicates a positive cell; blue indicates a negative cell. (F) One hotspot of positive cells is identified and marked by circle. Scale bar 100 μm.</p

Results obtained from the multivariate Cox proportional hazard ratio analysis.

Results obtained from the multivariate Cox proportional hazard ratio analysis.</p

Histopathological parameters and examined markers for patients in both the tumor recurrence and stage progression cohorts, presented in frequencies and percentages.

Histopathological parameters and examined markers for patients in both the tumor recurrence and stage progression cohorts, presented in frequencies and percentages.</p

Univariate progression-free survival analysis, including hazard ratio (HR) and 95% confidence interval (CI), for clinical and histopathological variables and examined markers.

Univariate progression-free survival analysis, including hazard ratio (HR) and 95% confidence interval (CI), for clinical and histopathological variables and examined markers.</p

(A) High MAI (>15), (B) high CK20 (positive), (C) high p53 (≥ 15) and (D) high CD25 (≥ 1.3) were associated with shorter stage progression free survival in Kaplan- Meier survival analysis.

(A) High MAI (>15), (B) high CK20 (positive), (C) high p53 (≥ 15) and (D) high CD25 (≥ 1.3) were associated with shorter stage progression free survival in Kaplan- Meier survival analysis.</p

Analysis for stage progression.

Comparison of the SUH 2002–2011 and SUH 2002–2006 cohorts. Univariate progression-free survival analysis, including hazard ratio (HR) and 95% confidence interval (CI), for clinical and histopathological variables, and examined markers. (DOCX)</p

Univariate recurrence-free survival analysis, including hazard ratio (HR) and 95% confidence interval (CI), for clinical and histopathological variables and examined markers.

Univariate recurrence-free survival analysis, including hazard ratio (HR) and 95% confidence interval (CI), for clinical and histopathological variables and examined markers.</p

The immunoreactive score (IRS) is the score for percentage positive tumor cells (X) multiplied by the score for staining intensity (Y), IRS = X x Y.

The immunoreactive score (IRS) is the score for percentage positive tumor cells (X) multiplied by the score for staining intensity (Y), IRS = X x Y.</p